The medication is applied to provide supportive local management for conditions where infection and tissue damage occur simultaneously, offering symptomatic relief and support for structural recovery. The combination formulation, including Centella Asiatica extract, means it is considered relevant for its ability to address two key areas simultaneously.

---

Therapeutic Scope and Key Benefits

Madecassol C is commonly used to help with symptom clusters associated with localized gynecological infectious-inflammatory conditions, including vaginitis, vaginosis bacteriana, and cervicitis. It is also applied in contexts involving physical tissue compromise, such as ulcers of the cervix and lesions following minor procedures, as well as for the management of superficial skin lesions like minor cuts and burns.

The treatment is relevant for managing symptomatic patterns such as abnormal discharge, local irritation, and redness. It provides supportive relief that generally contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Localized Tissue Strain

The medication assists with maintaining functional stability by supporting tissue regeneration and structural recovery, which is particularly helpful in situations where physical strain or minor injury disrupts the patient’s routine comfort.

Official Regulatory Eligibility and Restrictions

Eligibility for Madecassol C is strictly governed by regulatory documentation, defining who may or must not use the medicine. The medicine is generally indicated for adult women and post-menarchal adolescent females who do not possess any contraindications.

Populations Who Must Not Use the Medicine (Contraindications)

Use is contraindicated for individuals with known hypersensitivity to metronidazole, other nitroimidazole derivatives, or any ingredient in the formulation. Use is strictly prohibited for patients who have taken Disulfiram within the preceding two weeks or those who consume alcohol during treatment and for a required period afterward. Use during the first trimester of pregnancy is also contraindicated by some authorities.

Conditional or Restricted Use

Population Group	Regulatory Status
Pediatric	Safety and efficacy not established for children under 12 years; restricted to post-menarchal females.
Hepatic Function	Patients with severe hepatic disease require administration with caution due to metabolism concerns.
Neurological History	Caution is advised for patients with a history of Central Nervous System (CNS) disorders (e.g., seizures).
Lactation	Not recommended while breastfeeding.

This eligibility structure is derived exclusively from governmental regulatory profiles.

The official interaction profile for Madecassol C, based on its active component Metronidazole, documents several clinically significant constraints and prohibitions.

Regulatory labels officially classify the co-administration with Disulfiram as contraindicated, establishing a mandatory prohibition window. Use is strictly forbidden within a period of two weeks following the last Disulfiram dose.

A distinct pharmacodynamic interaction is documented with Alcoholic Beverages and products containing Propylene Glycol. The concurrent use of these substances may induce a formal Disulfiram-like reaction. Consequently, the consumption of alcohol or Propylene Glycol must be officially discontinued throughout the period of therapy and for a required minimum of three days following the final administration of the medicine.

In the pharmacokinetic domain, co-administration with Warfarin and other oral coumarin anticoagulants is officially described as potentiating the anticoagulant effect. This interaction results in the measurable prolongation of Prothrombin Time (PT) and International Normalized Ratio (INR). Furthermore, co-administration with Lithium and Busulfan is documented to potentially result in increased plasma concentrations of these medicines.

The regulatory profile includes a population-specific constraint: systemic exposure to the active component is officially reported to be substantially increased in patients with severe hepatic impairment. This finding confirms the heightened relevance of systemic and exposure-modifying interactions within this population.

How Madecassol C Works

The action of Madecassol C is defined by two primary, complementary mechanisms that involve microbial cytotoxicity and local tissue matrix modulation.

Microbial Cytotoxicity and Metabolic Disruption

This domain covers the synergistic anti-pathogen action of Metronidazole and Nitrofurazone. Metronidazole is reduced by specific enzymes inside susceptible pathogens (e.g., anaerobic bacteria and protozoa), generating toxic free radicals that directly damage microbial DNA. Simultaneously, Nitrofurazone intermediates inhibit key bacterial metabolic enzymes, starving the organism. This molecular cascade rapidly diminishes the local pathogen load, contributing to a shift in the local biological environment.

Tissue Regeneration and Extracellular Matrix Modulation

This mechanism is driven by the Centella Asiatica triterpenes (e.g., Asiaticoside), which act as physiological modulators. They stimulate fibroblasts and activate the Smad 2/3 signaling pathway to upregulate the production of Type I collagen and other components of the extracellular matrix. Furthermore, these triterpenes attenuate local inflammation by suppressing key mediators like COX-2. This results in enhanced structural integrity and accelerated tissue remodeling driven by new matrix synthesis.

Administration Guidelines for Madecassol C

Madecassol C, a combination product (Metronidazol/Centella Asiática/Nitrofural), is administered exclusively via localized routes, primarily in the óvulo (vaginal suppository) form. The medicine is not intended for oral or systemic use.

Administration Scope

Entity	Detail
Route of administration	Intravaginal (Óvulos) or Topical (Cream).
Standard Dosing Schedule	1 to 2 óvulos per day. Each óvulo contains a fixed concentration of 300 mg Metronidazol and other active components.
Frequency and Timing	Once or twice daily, typically scheduled for administration in the morning and at night.
Course Duration	The standard period of administration is a fixed course of 10 days.

Procedural Structure

Use of the intravaginal form requires specific procedural steps to ensure proper delivery and retention of the medicine. The óvulo must be inserted deeply into the vagina. Following application, the protocol includes remaining lying down for approximately 10 minutes; this procedural step facilitates the melting and local distribution of the suppository.

Furthermore, the protocol includes an administration constraint: concurrent use with latex-based products such as diaphragms or condoms should be avoided. This restriction is intended to prevent the product components from potentially compromising the integrity of the latex material. These instructions define the standardized approach to using the medicine.

Research Evidence / Overview of Studies for Madecassol C

This section provides an overview of the clinical research and scientific studies that have explored the components and therapeutic applications of Madecassol C, based on information reported in official scientific literature. This summary focuses on what research has been conducted, what outcomes were observed, and what remains to be fully established, without offering clinical guidance.

---

Evidence for Use in Gynecological Infectious-Inflammatory Conditions

Research has examined the anti-infective and tissue-integrity components of this medicine in the context of localized gynecological issues, such as vaginitis and bacterial vaginosis. The anti-infective components was evaluated in designs such as Randomized Controlled Trials (RCTs), which are designed to evaluate short-term changes in symptoms and measured pathogen clearance. Data show patterns related to measured pathogen levels and how outcomes related to physical discomfort evolved in the observed populations. However, research focusing directly on the exact triple-component combination product in large-scale trials remains limited. Long-term effects are not fully established, and there is limited information for long-term outcomes, such as tracking recurrence rates beyond six months.

---

Evidence for Supportive Tissue Regeneration and Healing

The Centella Asiatica component was evaluated in the context of general tissue integrity and healing. The research base includes Systematic Reviews and formal clinical trials that explored outcomes related to functional imbalance in various localized lesion and wound models. Studies monitored outcomes like the time elapsed until complete tissue closure (re-epithelialization) and changes in markers related to tissue quality. Findings indicate patterns of measured changes in tissue structure was observed in some studies. This research provides context regarding the Centella component as studied for outcomes related to physical discomfort in various superficial wound types. Comparative evidence is lacking for the full combination product when applied to specific internal lesions, such as cervical ulcers.

---

What Is Still Uncertain About Madecassol C

The research highlights several areas where further investigation was studied for. Comparative evidence is lacking for the specific triple-component formulation against other combination treatments. The contribution of each component to the final clinical outcome of the combination product is not fully established. The evidence quality varies across studies, and many clinical reports are based on smaller patient numbers or non-comparative designs. Consequently, the certainty surrounding long-term outcomes and the precise performance of the exact combination in all its licensed applications remains a focus for future research.

Common questions about Madecassol C (FAQ)

---

Q: Is Madecassol C available over the counter, or do I need a prescription?

The regulatory status of Madecassol C can differ based on the country or region. Since the product contains Metronidazole, which is an antimicrobial agent, products containing Metronidazole are often restricted and may require a prescription in many regulatory areas.

---

Q: What are the claimed benefits of using Madecassol C for scar healing?

Official information regarding the Centella Asiatica component documents its role in supporting tissue repair. This component is described in mechanistic studies as promoting processes essential for tissue repair, such as stimulating collagen production. This biological activity is relevant to supporting tissue structural integrity during healing.

---

Q: Are there any common reasons why a doctor might choose Madecassol C over a similar topical cream?

Madecassol C is a fixed-dose combination product designed for dual action. It combines anti-pathogen agents with a tissue regeneration component (Centella Asiatica). This unique combined approach addresses two concerns—microbial presence and tissue damage—a differentiating factor that informs its intended use.

---

Q: Why is Madecassol C sometimes recommended for post-procedure skin care?

The Centella Asiatica component is noted for supporting tissue structural integrity and remodeling. Mechanistic data shows it helps stimulate collagen synthesis. This mechanism aligns with the goals of skin repair and recovery following localized tissue disruption.

---

Q: What specific skin conditions is Madecassol C typically prescribed for?

The vaginal suppository (óvulo) form has recognized applications for treating localized gynecological infectious-inflammatory conditions. These generally include issues like vaginitis and bacterial vaginosis, due to the anti-infective components in the formulation.

---

Q: Is it okay to stop using Madecassol C once my symptoms improve, or should I finish the recommended course?

The anti-infective components require administration over a specific, predetermined duration. Regulatory information for anti-infective medications often stresses the importance of completing the full prescribed course to support optimal efficacy.

---

Q: Are there any long-term side effects associated with prolonged use of Madecassol C?

Official safety documents include warnings related to extended exposure to the Metronidazole component. Prolonged use is documented as being associated with a risk of developing peripheral neuropathy (a type of nerve damage) and convulsive seizures.

---

Q: Is there a maximum time limit for using Madecassol C?

The administration schedule for the prescribed course is for a predetermined duration. The risk of neurological side effects, such as peripheral neuropathy, is explicitly documented as being associated with long-term exposure. This indicates that continuous use beyond the prescribed period is constrained by official regulatory safety profiles.

---

Q: Can I use Madecassol C on fungal infections?

Official information documents the anti-pathogen components (Metronidazole and Nitrofurazone) as targeting specific susceptible protozoa and anaerobic bacteria, not fungal pathogens. The product is not generally listed for the treatment of fungal infections.

---

Q: Does the efficacy of Madecassol C change depending on the age of the user?

The official eligibility profile restricts use to adult women and post-menarchal adolescent females. This indicates that specific safety and efficacy data are not available for younger children.

---

Q: Is Madecassol C considered a natural or herbal-based treatment?

Madecassol C is officially classified as a combination product. It uses a blend of synthetic active components (Metronidazole and Nitrofurazone) alongside a plant-derived or herbal extract (Centella Asiatica).

---

Q: Is Madecassol C effective for treating minor burns?

The Centella Asiatica component is studied for its role in tissue integrity and healing. Research indicates this component stimulates collagen synthesis, a process relevant to the natural repair of localized skin lesions.

---

Q: Can Madecassol C be stored in the refrigerator, or should it be kept at room temperature?

Official storage instructions require that the medication be kept at a controlled room temperature. This is typically defined as a range between 20 C and 25 C. It is important to follow the specific storage guidelines provided on the product’s packaging.

How to Store and Dispose of Madecassol C

The storage of Madecassol C must strictly follow the official instructions documented by regulatory agencies to maintain the product's stability and integrity.

Storage Requirements

The medication must be stored at controlled room temperature, typically between 20°C and 25°C. Protection is required from environmental factors that could degrade the product, including light and moisture. The container must be kept tightly closed, and the medicine should always be stored in its original container.

Safety and Handling

It is a mandatory safety instruction that Madecassol C must be stored out of the reach of children and pets. The product should also be protected from excessive heat and should not be stored in high-humidity locations such as a bathroom.

Disposal Instructions

Unused or expired Madecassol C should be discarded according to official guidelines, preferably through a community drug take-back program. The medicine must not be flushed down the toilet or poured into a drain unless it is specifically listed by a national health authority as safe to do so.